首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1572448

戊型肝炎诊断测试市场、机会、成长动力、产业趋势分析与预测，2024-2032

Hepatitis E Diagnostic Tests Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 127 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球戊型肝炎诊断测试市场价值约为 6,000 万美元。戊型肝炎病毒（HEV）是戊型肝炎的罪魁祸首，由于卫生条件差和水源受污染，尤其是在发展中地区，其盛行率不断上升。世界卫生组织 (WHO) 报告称，全球每年发生约 2,000 万例戊型肝炎病毒感染，导致约 330 万有症状病例。这种不断上升的发生率凸显了对可靠诊断测试的迫切需求，从而推动了市场扩张。

提高意识和全面的筛检计划对于推动市场成长至关重要。公共卫生措施和教育活动揭示了戊型肝炎的情况，鼓励更多的人进行检测。加强筛检倡议，特别是在高风险地区，可以加强对该疾病的检测和管理。这些努力促进早期诊断，帮助监测盛行率并遏制肝炎的传播。

戊型肝炎诊断测试市场根据测试类型、样本测试、最终用途和地区进行分组。

市场按测试类型分为 ELISA HEV IgM 测试、ELISA HEV IgG 测试、快速诊断测试和聚合酶链反应 (PCR)。到 2032 年，ELISA HEV IgM 测试部分将达到 4,470 万美元。随着全球对戊型肝炎的认识和筛检的提高，特别是在高流行地区，对 ELISA HEV IgM 检测等及时诊断工具的需求将会增加。此外，测试敏感性和特异性的进步，以及用于控制病毒性肝炎的公共卫生资金的增加，也有助于该细分市场的成长。这一趋势强调了早期诊断和介入在管理戊型肝炎疫情、推动市场扩张方面的重要性。

根据样本类型，戊型肝炎诊断检测市场分为血液和粪便。 2023年，血液领域创造了5,110万美元的收入。基于血液的诊断，包括血清学检测和分子检测，因其检测 HEV 抗体和 RNA 的能力而受到高度重视。这种精确度对于诊断和监测疾病至关重要。它们的受欢迎源于它们检测急性和慢性阶段感染的能力，这对于有效管理至关重要。血液检测具有较高的灵敏度和特异性等优点，被认为是可靠的，使其成为医疗保健专业人员的首选。因此，基于血液的部分继续主导市场，反映出其在准确诊断戊型肝炎方面的核心作用。

在美国，戊型肝炎诊断测试市场预计到 2032 年将达到 3,420 万美元。分子诊断和先进检测等创新正在提高戊型肝炎检测的准确性和速度。同时，快速和即时检测的日益普及使得这些诊断在临床环境中更容易实现。这项技术进步预计将透过提高诊断能力和促进更快、更有效的测试来推动市场的大幅成长。

产业生态系统分析
产业影响力
- 成长动力
  - 戊型肝炎发生率上升
  - 诊断技术的进步
  - 提高认识和筛检计划
- 产业陷阱与挑战
  - 发展中地区供应有限
  - 严格的监管场景
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
未来市场趋势
差距分析
波特的分析
杵分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

主要趋势
ELISA HEV IgM 检测
ELISA HEV IgG 测试
快速诊断测试
聚合酶炼式反应 (PCR)

第 6 章：市场估计与预测：按样本类型，2021 - 2032 年

主要趋势
血
凳子

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊断实验室
血库
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

altona Diagnostics GmbH
CTK Biotech, Inc.
Dia.Pro Diagnostic Bioprobes s.r.l
DiaSorin S.p.A.
ELITechGroup ( Bruker company)
F. Hoffmann-La Roche Ltd
Fortress Diagnostics
Genscript Biotech Corporation
Guangzhou Wondfo Biotech Co., Ltd.
Medsource Ozone Biomedicals Pvt. Ltd.
MIKROGEN GmbH
MP Biomedicals
Primer Design
Wantai BioPharm

简介目录

Product Code: 10834

The Global Hepatitis E Diagnostic Tests Market was valued at approximately USD 60 million in 2023. Projections indicate a growth rate of 4.3% CAGR from 2024 to 2032. The global surge in hepatitis E cases has increased the demand for efficient diagnostic solutions. The hepatitis E virus (HEV) is the culprit behind hepatitis E, with its prevalence rising due to poor sanitation and tainted water sources, notably in developing areas. The World Health Organization (WHO) reports that around 20 million global infections of the hepatitis E virus occur annually, leading to roughly 3.3 million symptomatic cases. This rising incidence highlights the urgent need for dependable diagnostic tests, driving market expansion.

Heightened awareness and comprehensive screening programs are pivotal in driving market growth. Public health initiatives and educational campaigns have shed light on hepatitis E, encouraging more individuals to pursue testing. Enhanced screening initiatives, especially in high-risk regions, bolster the detection and management of the disease. These efforts promote early diagnosis and help monitor prevalence and curb the spread of hepatitis.

The Hepatitis E Diagnostic Tests Market is grouped based on test type, sample test, end-use, and region.

The market is segmented by test type into ELISA HEV IgM test, ELISA HEV IgG test, rapid diagnostics test, and polymerase chain reaction (PCR). The ELISA HEV IgM test segment will reach USD 44.7 million by 2032. The test is significant because it identifies recent HEV infections by detecting IgM antibodies, which appear shortly after infection onset. As global awareness and screening for hepatitis E increase, especially in high-prevalence regions, the demand for timely diagnostic tools like the ELISA HEV IgM test will rise. Additionally, advancements in test sensitivity and specificity, along with increased public health funding for viral hepatitis control, contribute to this segment's growth. This trend underscores the importance of early diagnosis and intervention in managing hepatitis E outbreaks, driving market expansion.

Based on sample type, the hepatitis E diagnostic tests market is divided into blood and stool. In 2023, the blood segment generated USD 51.1 million. Blood-based diagnostics, including serological assays and molecular tests, are highly valued for their ability to detect HEV antibodies and RNA. This precision is crucial for diagnosing and monitoring the disease. Their popularity stems from their ability to detect infections in both acute and chronic stages, which is essential for effective management. With advantages like higher sensitivity and specificity, blood tests are considered reliable, making them the preferred choice among healthcare professionals. Consequently, the blood-based segment continues to dominate the market, reflecting its central role in accurately diagnosing hepatitis E.

In the U.S., the hepatitis E diagnostic tests market is projected to reach USD 34.2 million by 2032. Key drivers include technological advancements in diagnostics and the rise of point-of-care testing. Innovations such as molecular diagnostics and advanced assays are enhancing the accuracy and speed of hepatitis E detection. At the same time, the growing availability of rapid and point-of-care tests is making these diagnostics more accessible in clinical settings. This technological progress is expected to drive substantial market growth by improving diagnostic capabilities and facilitating quicker, more efficient testing.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising hepatitis E incidence
  - 3.2.1.2 Advancement in diagnostic technologies
  - 3.2.1.3 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Limited availability in developing regions
  - 3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTLE analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 ELISA HEV IgM test
5.3 ELISA HEV IgG test
5.4 Rapid diagnostics test
5.5 Polymerase chain reaction (PCR)

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Blood
6.3 Stool

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Blood banks
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa